AL044 / Alector - LARVOL DELTA

Alector Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) - "Progranulin Assets (Latozinemab, AL101): The company expects to report follow-up data from the INFRONT-2 Phase 2 clinical trial of latozinemab in frontotemporal dementia patients with a C9orf72 genetic mutation (FTD-C9orf72) in 2023....Alector will present a poster, Repeat IV and SC dosing of the Anti-Sortilin Antibody AL101, with data from the Phase 1 trial of AL101 in healthy volunteers at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference, being held in San Francisco, California from November 29 to December 2, 2022...the company plans to investigate AL101 for the treatment of Alzheimer’s disease (AD) and Parkinson’s disease (PD)....Novel MS4A Asset (AL044): Safety and biomarker data from this study are anticipated in 2023....Total research and development expenses for the quarter ended September 30, 2022, were $48.3 million...The increase in R&D expenses was mainly driven by increased personnel-related expenses as well as an increase in AL002 expenses."

Biomarker • Commercial • P1 data • P2 data • Alzheimer's Disease • CNS Disorders • Dementia • Frontotemporal Lobar Degeneration • Parkinson's Disease

Alector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimer's Disease (AD) (Benzinga) - "Alector, Inc...announced the initiation of the first-in-human Phase 1 trial of AL044. The study is investigating the safety profile, pharmacokinetics (PK), pharmacodynamics (PD) and target engagement of AL044 in healthy adults....Approximately 72 healthy participants will be enrolled in the Phase 1 trial of AL044."

Trial status • Alzheimer's Disease • CNS Disorders